title: [The uterine sarcoma, a new risk identified for tamoxifen].
authors.forename: M
authors.initials: M
authors.lastname: Baron
authors.forename: P
authors.initials: P
authors.lastname: Dessogne
authors.forename: J
authors.initials: J
authors.lastname: d'Anjou
mesh_terms: D000368:Aged; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy; D002296:Carcinosarcoma / Q000139:chemically induced*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008796:Metrorrhagia / Q000139:chemically induced; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D009570:Nitriles / Q000627:therapeutic use; D012306:Risk; D013629:Tamoxifen / Q000009:adverse effects*; D014230:Triazoles / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000139:chemically induced*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D020847:Estrogen Receptor Modulators; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole